



A CLINICAL STUDY OF THYROID PROFILE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Dr Avinash Chandra Srivastava

MD (Medicine) Senior Consultant Physician, Dr.Ram Manohar Lohia Combined Hospital, Vibhuti Khand, Lucknow, 226010

ABSTRACT **Background:** Diabetes mellitus (DM), a common endocrine metabolic disorder, is an important cause of morbidity and mortality worldwide. Patients with diabetes have a higher prevalence of thyroid disorders when compared with general population. **Objectives:** Present study was done to evaluate the thyroid profile in type 2 diabetic patients. **Material and Methods:** It was a case control study which was done for a period of one year from January 2017 to December 2017 in Ram Manohar Lohia Combined Hospital, Lucknow. Study included a total of 100 subjects divided into 2 groups – 50 cases and 50 controls. The comparison was done by student t test and statistical analysis of each parameter was done by SPSS statistical package version 17.0. **Results:** The levels of serum TSH and fasting blood sugar were significantly increased while serum T3 and T4 levels were significantly decreased in cases when compared to controls. **Conclusion:** The present study suggests that the abnormal thyroid hormone levels seen in type 2 diabetics are due to alteration in Hypothalamo-pituitary-thyroid axis, which in turn produces significant metabolic disturbances. Hence, routine screening for thyroid dysfunction should be carried out in diabetics, which helps in its early diagnosis and treatment there by improves their quality of life and reduces the morbidity rate.

KEYWORDS : Diabetes Mellitus, Hypothyroidism, Hyperthyroidism.

Background:

Diabetes mellitus (DM), a leading cause of death worldwide, is one of the most challenging health problems in the 21st century.¹⁻³ It is a group of metabolic diseases characterized by persistent hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Development of diabetes involves several pathogenic processes ranging from autoimmune destruction of the β -cells of the pancreas with consequent insulin deficiency to abnormalities that result in resistance to insulin action.^{4,5}

Diabetes mellitus (DM) is a common endocrine disorder which involves multiple organ systems and leads to significant morbidity and mortality due to accompanying complications.⁶⁻¹⁰

Much has been accomplished in the field of diabetes but what has been troubling one and all are the large macrovascular and microvascular complications of diabetes involving kidneys, eyes, blood vessels, nerves, and heart. Thyroid diseases are also a common endocrinopathy seen in the adult population. Thyroid hormones are intimately involved in cellular metabolism.¹¹⁻²⁷ Thus, excess or deficit of either insulin or thyroid hormones could result in the functional derangement of the cellular metabolism.

Aim and Objectives:

Present study was done to evaluate the thyroid profile in type 2 diabetic patients.

Materials and Methods:

It was a case control study which was done for a period of one year from January 2017 to December 2017 in Ram Manohar Lohia Combined Hospital, Lucknow. Study included a total of 100 subjects divided into 2 groups – 50 cases and 50 controls. Informed consent was taken from both cases and controls and the study was approved by the institutional ethical and research committee. A detailed proforma was filled up for each patient which included age, sex, past history of coronary artery disease, cerebrovascular accident, history of hypertension. The age of onset and duration of diabetes were recorded. As also recorded was whether the patient was treated with oral hypoglycemic agents or insulin or whether the patient was on diet control alone. Venous blood samples were collected from patients after an overnight (8 hr) fasting in sodium fluoride tubes and plain tubes from cases and controls. T3, T4 and TSH were estimated by using Chemiluminescence Immunoassay (CLIA) method and Fasting plasma glucose by GOD-POD method.

Inclusion criteria:

- Cases: 30 Diagnosed type-2 diabetic patients of age 40 -60 yrs of both genders who are on treatment, with no known complications and no history of previous thyroid disease were included.
- Controls: 30 age and sex matched normal healthy individuals

without any history of diabetes and without known systemic disorders were included.

Exclusion criteria:

Individuals with previous history of thyroid disease and on drugs that affect thyroid function, pregnancy, patients with diabetic complications.

Criteria used in the study for diagnosis of type 2 DM (According to American Diabetic Association) are 1) FBS (Fasting Blood Sugar) \geq 126 mg/dl (7.0 mmol/L) or 2) Symptoms of diabetes plus RBS (Random Blood Sugar) \geq 200 mg/dl (11.1 mmol/L).

Statistical analysis:

The results obtained and expressed in mean \pm SD. The comparison was done by student t test and statistical analysis of each parameter was done by SPSS statistical package version 17.0. p value $<$ 0.05 was considered statistically significant.

Results:

The present study was conducted on 100 subjects aged between 40-60 years. This Case control study has 50 diagnosed type 2 diabetic patients of both genders who were on treatment with no known complications and no history of previous thyroid disease.

The levels of serum TSH and fasting blood sugar were significantly increased while serum T3 and T4 levels were significantly decreased in cases when compared to controls.

	Male	Female	Mean ages
Cases	28	22	42.97 \pm 4.15
Controls	25	25	43.15 \pm 5.06

Table 1: Sex and age wise distribution of cases and controls.

Parameter	Cases	Controls	P value
FBS	186.05 \pm 78.5	99.1 \pm 18.5	$<$ 0.001
T3	1.15 \pm 0.95	1.40 \pm 0.35	$<$ 0.001
T4	7.65 \pm 3.9	8.20 \pm 2.05	0.023
TSH	7.40 \pm 6.5	3.57 \pm 1.85	0.045

Table 2: Test parameters in both cases and controls.





Figure 1: Comparison of sugar levels in both cases and controls**Figure 2: Bar diagram showing comparison of thyroid parameters in cases and controls****Discussion:**

Diabetes, a heterogeneous endocrine metabolic disorder, is a leading cause of morbidity and mortality the world over. It has got worldwide distribution and its incidence is increasing day by day all over the world posing a major threat to the public health.²³ As a result of rapid urbanization and economic development, India will continue to have the largest number of diabetic subjects.²⁴ Diabetes is commonly associated with altered thyroid function. Thyroid disorders are also very common endocrine disorders in the general population after diabetes. Hence it is common for an individual to be affected by both thyroid diseases and diabetes.¹ The aim of the study is to evaluate the levels of serum T3, T4 & TSH and fasting blood sugar in type 2 diabetic patients. The present study includes 60 subjects of which 30 were known type 2 diabetic patients (cases) and 30 were normal healthy controls. The results of the present study showed that the levels of serum T3, T4 were significantly lower in diabetics while serum TSH was significantly higher in diabetics when compared to that of controls. This is in accordance with the studies of Vikram BV et al.,⁶ Gurjeet S et al.,¹ and Shekhar CY et al.¹⁹ The fasting blood sugar level was significantly elevated in cases when compared to controls. This is in accordance with the studies of Priti S et al.,²⁵ Samatha P et al.,²⁶ and Reeta T et al.²⁷ Out of 30 diabetic subjects investigated in the present study, 16.7% i.e. 5 had hypothyroidism and 10% i.e. 3 had hyperthyroidism. Thus, a total of 26.7% diabetic patients showed thyroid dysfunction. Also, 6.7% i.e. 2 out of 30 controls had hypothyroidism. These observations show a high incidence of abnormal thyroid hormone levels in diabetics which is in accordance with studies of Vibha U et al.¹⁰ and Pasupathi P et al.²⁷ The influence of endocrine and non-endocrine organs other than pancreas on diabetes is documented. Occasionally, other endocrine disorders such as altered thyroid hormone levels are found in diabetes. The presence of both high and low thyroid hormone levels in diabetics in this study may be due to modified Thyroid releasing hormone (TRH) synthesis and release and may depend on the glycemic status of diabetics. Glycemic status is influenced by insulin, which is known to modulate the levels of TRH and TSH.^{13,27}

In diabetes there are alterations in the hypothalamo-pituitary-thyroid axis. The major alterations include a reduction in the hypothalamic and plasma TRH, pituitary and plasma TSH and TSH secretion rate. Despite normal peripheral TSH metabolism, response of TSH to TRH is also decreased. Production of T3 and T4 and iodide uptake by thyroid gland are diminished. There are also important structural changes in both thyroid and pituitary glands which are accompanied by marked alterations in their secretory activities. In addition to these, deiodination of T4 to T3 is decreased.²⁷ Suzuki et al attributed the abnormal thyroid hormone levels found in diabetes to the presence of thyroid hormone binding inhibitor (THBI), an inhibitor of the extra thyroidal conversion enzyme (5'-deiodinase) of T4 to T3, and dysfunction of the hypothalamo-pituitary thyroid axis. These situations may prevail in diabetes and would be aggravated in poorly controlled diabetics. Stress, which is associated with diabetes, may also cause changes in the hypothalamus-anterior pituitary axis in these diabetics.

Conclusion:

The present study demonstrates that the serum T3 and T4 levels were decreased while serum TSH level was increased in type 2 diabetics when compared to controls. There is a higher prevalence of abnormal thyroid hormone levels in type 2 diabetics. Presence of abnormal

thyroid hormone levels in diabetics, if unrecognized, may be a primary cause of poor management often encountered in some treated diabetics. Hence there is need for the routine assay of thyroid hormones in diabetics which will help in the early detection and treatment of thyroid dysfunction. This helps improve the quality of life and reduce the morbidity rate in diabetic patients.

Acknowledgement:

We extend our sincere thanks to Dr Abhishek Arun (MD) for his assistance in medical writing. We are also thankful to junior doctors and staff of Medicine department Ram Manohar Lohia Combined Hospital, Lucknow. Special thanks to everyone who participated in the study.

Limitations:

- Study population was small.
- Associated thyroid autoimmunity was not evaluated due to constraints. Hence, it was not able to refine the spectrum of thyroid dysfunction in Type 2 diabetics.
- Follow-up study was not done. Hence, the natural history of subclinical thyroid dysfunction and its effect on various parameters could not be assessed.

References:

1. Gurjeet S, Vikas G, Anu Kumar S, Neeraj G. Evaluation of Thyroid Dysfunction Among type 2 diabetic Punjabi Population. *Adv. Biore.* 2011 December; 2(2):3-9.
2. Faghilimnai S, Hashemipour M, Kelishadi B. Lipid profile of children with type 1 diabetes compared to controls: ARYA. *J.* 2006; 2(1): 36-38.
3. Shonima V, Uma MI. Risk factor analysis and prevalence of microalbuminuria among type 2 Diabetes Mellitus Subjects: The need for screening and monitoring Microalbumin. *ASIAN J. EXP. BIOL. SCI.* 2010; 1(3):652-659
4. Sachin B, Mahesh M, Sachin S, Vaishali G. Evaluation of Thyroid Hormones in Patients with Type II Diabetes Mellitus. *Journal of Medical Education & Research.* 2013 July-Dec; 3(2):33-39.
5. American diabetes association. Diagnosis and classification of diabetes mellitus. *Diabetes care* 2010; 33: 562-569.
6. Bennett PH, Knowlton WC. Definition, diagnosis and classification of diabetes. *Joslin's Diabetes Mellitus.* Philadelphia, PA: Lea & Febiger; 2005. p. 14331-7.
7. Powers AC. Diabetes mellitus. *Harrison's Principles of Internal Medicine.* 18th ed. New York: The McGraw Hill Companies; 2011. p. 2968-3002.
8. Federation International Diabetes. *IDF Diabetes Atlas.* 7th ed. Brussels, International Diabetes Federation; 2015.
9. WHO. *Technical Report Series, No. 916.* Geneva: WHO; 2003.
10. Federation International Diabetes. *IDF Diabetes Atlas.* 7th ed. Brussels, International Diabetes Federation; 2015.
11. Federation International Diabetes. *IDF Diabetes Atlas.* 7th ed. Brussels, International Diabetes Federation; 2015.
12. UN. 61st Session; Agenda 113. 83rd Plenary Meeting, 20th December; 2006.
13. Barnett DM, Krall LP. History of diabetes. *Joslin's Diabetes Mellitus.* 14th ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2005. p. 1-17.
14. Porter R. *The Greatest Benefit to Mankind, a Medical History of Humanity.* New York: WW Norton; 1997. p. 71.
15. Schadevaldt H. The history of diabetes mellitus. In: Van Englehardt D, editor. *Diabetes, Its Medical and Cultural History.* Berlin: Springer-Verlag; 1987. p. 43-100.
16. Langerhans P. *Beitrage zur Mikroskopischen Anatomie der Bauchspeicheldruse.* Medicine Dissertation Berlin; 1869.
17. Morrison H. Translation and introductory essay. Langerhans P. *Contributions to the microscopic anatomy of the pancreas.* *Bull Inst Hist Med* 1937; 5:259-69.
18. Minkowski O. Historical development of the theory of pancreatic diabetes, (introduction and translation by R. Levine). *Diabetes* 1989; 38:1-6.
19. Banting FG, Best CH. The internal secretion of the pancreas. *J Lab Clin Med* 1922; 7:251-66.
20. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of Type 2 diabetes: Normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. *Diabetologia* 2011; 54:2506-14.
21. Mortensen HB, Hougaard P, Swift P, Hansen L, Holl RW, Hoey H, et al. New definition for the partial remission period in children and adolescents with Type 1 diabetes. *Diabetes Care* 2009; 32:1384-90.
22. Gavin JR IIIrd, Alberti KG, Davidson MB, DeFronzo RA, Drash A, Gabbe SG, et al. Report of the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care* 2010; 33 Suppl 1:S62-9.
23. WHO Consultation Group. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and Classification of Diabetes Mellitus WHO/NCD/NCS/99. 2nd ed. Geneva: World Health Organisation; 1999. p. 1-59.
24. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with Type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). *UK Prospective Diabetes Study (UKPDS) Group.* *JAMA* 1999; 281:2005-12.
25. Reinehr T. Type 2 diabetes mellitus in children and adolescents. *World J Diabetes* 2013; 4:270-81.
26. American Diabetes Association. Standards of medical care in diabetes--2014. *Diabetes Care* 2014; 37 Suppl 1:S14-80.
27. Chahil TJ, Ginsberg HN. Diabetic dyslipidemia. *Endocrinol Metab Clin North Am* 2006; 35:491-510, vii-viii.